Article
Oncology
Robin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, Ahmed Kaseb, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Kamalika Banerjee, Saswati Hazra, Jonathan Fawcett, Thomas Yau
Summary: This study evaluated the combination of cabozantinib and atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. The combination treatment group showed better progression-free survival compared to the sorafenib group, but overall survival did not reach statistical significance. Common adverse events in the combination group included liver enzyme elevation, hypertension, and skin reactions. The study suggests that cabozantinib plus atezolizumab may be a treatment option, but further research is needed.
Article
Chemistry, Multidisciplinary
An-Tian Huang, Jun Du, Zhi-Yong Liu, Guang-Cong Zhang, Weinire Abuduwaili, Jia-Yan Yan, Jia-Lei Sun, Ru-Chen Xu, Tao-Tao Liu, Xi-Zhong Shen, Ling Dong, Ji-Min Zhu, Yuhao Li
Summary: This study developed a novel nanoparticle based on photothermal therapy, which can enhance the therapeutic effect and reduce the adverse effects of hepatocellular carcinoma.
Article
Oncology
Dae-Won Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae-Yong Kim, Sae-Won Han, Youn Oh, Seock-Ah Im, Tae-You Kim, Youngeun Lee, Haeryoung Kim, Kyung-Hun Lee
Summary: This study demonstrated that avelumab had moderate efficacy and good tolerability in patients with advanced hepatocellular carcinoma previously treated with sorafenib. The duration of sorafenib treatment prior to avelumab therapy appeared to influence the treatment outcomes.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Ryota Matsuki, Naohiro Okano, Nobuhiro Hasui, Shohei Kawaguchi, Hirokazu Momose, Keiichiro Kitahama, Kiyotaka Nagahama, Masaharu Kogure, Yutaka Suzuki, Fumio Nagashima, Junji Shibahara, Hideaki Mori, Yoshihiro Sakamoto
Summary: This study reports a case of advanced FLHCC treated with ABT, which resulted in pseudoprogression of LN metastases. The case confirms the potential therapeutic effect of ABT in FLHCC and highlights the occurrence of pseudoprogression during treatment.
Article
Gastroenterology & Hepatology
Jens Ricke, Regina Schinner, Max Seidensticker, Antonio Gasbarrini, Otto M. van Delden, Holger Amthauer, Bora Peynircioglu, Irene Bargellini, Roberto Iezzi, Enrico N. De Toni, Peter Malfertheiner, Maciej Pech, Bruno Sangro
Summary: The study revealed that selective internal radiation therapy (SIRT) has a negative impact on liver function in patients with hepatocellular carcinoma, which may affect patient outcomes. Patients should be carefully selected before undergoing SIRT and treatment techniques should be optimized to maximize protection of non-target liver parenchyma.
JOURNAL OF HEPATOLOGY
(2021)
Article
Engineering, Biomedical
Jun Hu, Jing Hu, Wenrui Wu, Yufei Qin, Junjie Fu, Chao Liu, Peter H. Seeberger, Jian Yin
Summary: This study presents the development of a nanoplatform, Sor@GR-COF-366, for synergistic chemotherapy and photodynamic therapy (PDT) in hepatocellular carcinoma (HCC). The nanoplatform combines a porphyrin-based covalent organic framework (COF-366) with N-acetyl-galactosamine (GalNAc), rhodamine B (RhB), and Sorafenib (Sor). It shows targeted delivery to ASGPR-overexpressed HCC cells and liver tissues, exerting enhanced tumor suppression effects and prolonging survival in mouse models with low toxicity. The combination of biomedical nano-formulation with clinical operational means holds great promise for clinical translation in cancer treatment.
ACTA BIOMATERIALIA
(2022)
Article
Oncology
Qinqin Liu, Nan You, Jing Li, Ke Wu, Xuehui Peng, Zheng Wang, Liang Wang, Yinan Zhu, Lu Zheng
Summary: The study found that the combination of camrelizumab and sorafenib significantly improved the overall response rate and progression-free survival of patients with advanced HCC, but had no significant impact on overall survival. The combination therapy group exhibited more adverse events in terms of efficacy, but most of these adverse events were easily controlled after treatment. Further prospective randomized trials are needed to confirm the potential clinical benefits of this combination therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Catherine Leyh, Ursula Ehmer, Daniel Roessler, Alexander B. Philipp, Florian P. Reiter, Petia Jeliazkova, Leonie S. Jochheim, Matthias Jeschke, Janina Hammig, Johannes M. Ludwig, Jens M. Theysohn, Andreas Geier, Christian M. Lange
Summary: This study compared the sequential systemic therapy after first-line therapy with sorafenib or lenvatinib and discontinuation of therapy in patients with liver cancer. The results showed that liver functional status and patient performance status at the beginning of first-line therapy had an impact on median overall survival (mOS), while the choice of the initial tyrosine kinase inhibitor (TKI) did not affect mOS.
Review
Oncology
Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele
Summary: One of the most important abilities of a tumor is to establish immunosuppression inside the tumor microenvironment. This is achieved through various mechanisms of tumor immune escape identified in experimental studies. In the liver, the microenvironment is oriented towards immune tolerance, preventing autoimmune reactions. Additionally, hepatocellular carcinoma often develops in the context of chronic inflammation. Due to these factors, different immunotherapeutic strategies have been developed and evaluated for advanced HCC. This review provides an overview of the clinical applications of immunotherapy for advanced HCC, including approved drugs and ongoing clinical trials.
Review
Oncology
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Summary: Recent years have seen the emergence of new therapeutic opportunities for advanced hepatocellular carcinoma (HCC) such as immune checkpoint inhibitors. A meta-analysis comparing immune-based combinations to sorafenib in advanced HCC patients showed that immune-based combinations reduced the risk of death by 27% and provided a progression-free survival benefit. Immune-based combinations also showed better rates of complete response and partial response compared to sorafenib monotherapy. The findings further support the use of immune-based combinations as a first-line treatment for HCC.
Article
Oncology
Luca Ielasi, Francesco Tovoli, Matteo Tonnini, Bernardo Stefanini, Raffaella Tortora, Giulia Magini, Rodolfo Sacco, Tiziana Pressiani, Franco Trevisani, Ingrid Garajova, Fabio Piscaglia, Alessandro Granito
Summary: This study aimed to evaluate the prognostic role of different sites of metastases in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. The results showed that lymph nodes and lung metastases were associated with worse survival rates and treatment response, while bone and adrenal gland metastases did not significantly impact prognosis. Therefore, targeted treatment strategies should be considered for different metastatic sites.
Review
Oncology
Tao Yan, Lingxiang Yu, Ning Zhang, Caiyun Peng, Guodong Su, Yi Jing, Linzhi Zhang, Tong Wu, Jiamin Cheng, Qian Guo, Xiaoliang Shi, Yinying Lu
Summary: Recent advancements in precision medicine, clinical diagnoses, treatments, and innovative research have led to important breakthroughs in the care of hepatocellular carcinoma (HCC). This includes the discovery of new biomarkers, the promotion of liquid biopsy technologies, and advancements in targeted therapy and immunotherapy. Multiomics technologies have provided a deeper understanding of the characteristics of HCC. The promotion of accurate typing, treatment guidance, and prognosis has provided more treatment opportunities and extended survival timelines for HCC patients.
CANCER BIOLOGY & MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Yin Long, Xingdong Song, Yan Guan, Ran Lan, Ziqi Huang, Senlin Li, Lei Zhang
Summary: This systematic review found that the combination of sorafenib and hepatic arterial infusion chemotherapy (HAIC) improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) compared with sorafenib alone in advanced hepatocellular carcinoma (HCC), with an acceptable safety profile.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Oncology
Chi-Leung Chiang, Sik-Kwan Chan, Shing-Fung Lee, Horace Cheuk-Wai Choi
Summary: Research shows that atezolizumab-bevacizumab may be cost-effective in treating patients with unresectable hepatocellular carcinoma, depending on factors such as long-term clinical benefits, price reductions, duration of therapy, and dosage optimization. The long-term effectiveness, price reduction, duration of therapy, and dosage optimization are critical determinants of the cost-effectiveness of atezolizumab-bevacizumab in patient treatment.
Review
Oncology
Jia Luo, Benjian Gao, Zhiyu Lin, Hua Fan, Wen Ma, Danfei Yu, Qian Yang, Jing Tian, Xiaoli Yang, Bo Li
Summary: This meta-analysis compares the efficacy and safety of lenvatinib and sorafenib in patients with advanced hepatocellular carcinoma (HCC). The results showed that lenvatinib had significantly better progression-free survival and disease control rate compared to sorafenib, with similar incidences of adverse events. Lenvatinib is a promising alternative to sorafenib as a first-line therapy for advanced HCC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Roland C. Y. Leung, Thomas C. C. Yau, Miranda C. M. Chan, Sharon W. W. Chan, Terence W. C. Chan, Yvonne Y. Y. Tsang, Ting Ting Wong, Calvin Chao, Carl Yoshizawa, Inda S. Soong, Wing-Hong Kwan, Carol C. H. Kwok, Joyce S. J. Suen, Roger K. C. Ngan, Polly S. Y. Cheung
CLINICAL BREAST CANCER
(2016)
Article
Oncology
Thomas C. C. Yau, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, Yee Chao, Chia-Jui Yen, Wirote Lausoontornsiri, Pei-Jer Chen, Theeranun Sanpajit, Aaron Camp, Donna S. Cox, Robert C. Gagnon, Yuan Liu, Kristen E. Raffensperger, Diptee A. Kulkarni, Howard Kallender, Lone Harild Ottesen, Ronnie T. P. Poon, Donald P. Bottaro
CLINICAL CANCER RESEARCH
(2017)
Article
Medicine, General & Internal
Ka-On Lam, Kin-Chung Lee, Joanne Chiu, Victor Ho-Fun Lee, Roland Leung, T. S. Choy, Thomas Yau
POSTGRADUATE MEDICAL JOURNAL
(2017)
Article
Medicine, General & Internal
Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S. Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jorg Trojan, Theodore H. Welling, Tim Meyer, Yoon-Koo Kang, Winnie Yeo, Akhil Chopra, Jeffrey Anderson, Christine dela Cruz, Lixin Lang, Jaclyn Neely, Hao Tang, Homa B. Dastani, Ignacio Melero
Article
Oncology
Lui Ng, Timothy Ming-Hun Wan, Johnny Hon-Wai Man, Ariel Ka-Man Chow, Deepak Iyer, Guanghua Chen, Thomas Chung-Cheung Yau, Oswens Siu-Hung Lo, Dominic Chi-Chung Foo, Jensen Tung-Chung Poon, Wai-Keung Leung, Roberta Wen-Chi Pang, Wai-Lun Law
Editorial Material
Oncology
Joanne W. Chiu, Gerry Kwok, Thomas Yau, Roland Leung
TRANSLATIONAL CANCER RESEARCH
(2017)
Article
Oncology
Lui Ng, Ariel K. M. Chow, Johnny H. W. Man, Thomas C. C. Yau, Timothy M. H. Wan, Deepak N. Iyer, Virginia H. T. Kwan, Ronnie T. P. Poon, Roberta W. C. Pang, Wai-Lun Law
Article
Oncology
Tan-To Cheung, Philip Chong-Hei Kwok, Stephen Chan, Chin-Cheung Cheung, Ann-Shing Lee, Victor Lee, Hoi-Ching Cheng, Nam-Hung Chia, Charing C. N. Chong, Tak-Wing Lai, Ada L. Y. Law, Mai-Yee Luk, Chi Chung Tong, Thomas C. C. Yau
Article
Oncology
Jeffrey Sum-Lung Wong, Yawen Dong, Vikki Tang, Thomas Leung, Cynthia S. Y. Yeung, Anna Tai, Ada Law, Tracy Shum, Gerry Gin-Wai Kwok, Bryan Cho-Wing Li, Roland Leung, Joanne Chiu, Ka-Wing Ma, Wong-Hoi She, Josephine Tsang, Tan-To Cheung, Thomas Yau
Summary: Cabozantinib showed good anti-tumor activity, survival benefits, and acceptable tolerability in real-life advanced HCC patients. The study evaluated the real-world use, efficacy, and safety of cabozantinib in aHCC patients.
Article
Oncology
Thomas Yau, Paul N. M. Cheng, Joanne Chiu, Gerry Gin Wai Kwok, Roland Leung, Angela M. Liu, Tan To Cheung, Chi Tao Ng
Summary: The PACOX regimen showed promising anti-cancer activity and survival advantage in advanced pre-treated HCC patients, with a favorable safety profile. Further phase II/III studies are warranted to confirm these findings.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Virology
Ye-Fan Hu, Jing-Chu Hu, Hin Chu, Thomas Yau, Bao-Zhong Zhang, Jian-Dong Huang
Summary: The impact of the Omicron variant on antibodies and vaccines is still unknown. However, analysis suggests that it may weaken the neutralizing potential of current therapeutic antibodies to varying degrees and could have a similar impact on COVID-19 vaccines.
Article
Oncology
Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Antonio Cubillo Gracian, Anthony B. El-Khoueiry, Bruno Sangro, Tarek E. Eldawy, Jordi Bruix, Giovanni Luca Frassineti, Gina M. Vaccaro, Marina Tschaika, Christian Scheffold, Petra Koopmans, Jaclyn Neely, Fabio Piscaglia
Summary: The study aimed to investigate the safety and efficacy of nivolumab plus cabozantinib with or without ipilimumab in patients with advanced hepatocellular carcinoma. The results showed that this combination therapy had promising antitumor activity and a favorable safety profile in the treatment of advanced hepatocellular carcinoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Arndt Vogel, Robin Katie Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa
Summary: A systematic literature review reveals the importance of liver function assessments in predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma. The study supports liver function as a prognostic marker and highlights the value of stratifying patients based on baseline liver function in clinical trials for aHCC.
Article
Oncology
Ann-Lii Cheng, Gerardo Cornelio, Lin Shen, Timothy Price, Tsai-Sheng Yang, Ik Joo Chung, Guang-Hai Dai, Jen-Kou Lin, Atul Sharma, Kun-Huei Yeh, Brigette Ma, Adel Zaatar, Zhongzhen Guan, Nehal Masood, Vichien Srimuninnimit, Thomas Yau, Peter Gibbs, Xiuwen Wang, Dinesh Chandra Doval, Seung-Taek Oh, Byoung Yong Shim, Charity Gorospe, Hwei-Ming Wang, Ekaphop Sirachainan, Andrew Hill, Kwang Wook Suh, Frank Beier, Sudipto Chatterjee, Robert Lim
CLINICAL COLORECTAL CANCER
(2017)
Article
Gastroenterology & Hepatology
Vincent S. K. Yip, Tan To Cheung, Ronnie T. P. Poon, Thomas Yau, James Fung, Wing Chiu Dai, Albert C. Y. Chan, Siu Ho Chok, See Ching Chan, Chung Mau Lo
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY
(2016)